Shots:
- McGill to receive $350,000 up front, $10.5M as development and regulatory milestone & is also eligible for ~$30M as a commercial milestone. Clarus will develop and commercialize McGill’s technology targeted the conditions associated with CoQ10 deficiencies
- The collaboration will accelerate the development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies belong to a broader class of mitochondrial diseases
- The collaboration also broadens Clarus’ focus beyond androgen-based medicines to a metabolic therapy for CoQ10 deficiencies
Click here to read full press release/ article | Ref: Globe Newswire | Image: PR Newswire
The post Clarus Signs an Exclusive WW License Agreement with McGill University to Develop and Commercialize its Technology for Rare Conditions Due to Coenzyme-Q10 Deficiencies first appeared on PharmaShots.
